Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash provided by operating activities | 80,382 | 30,969 |
| Investing Activities | ||
| Proceeds from disposal of assets | — | 435 |
| Purchases of property and equipment | (7,148) | (6,204) |
| Purchases of investments | (160,033) | (137,806) |
| Maturities of investments | 103,598 | 88,806 |
| Net cash (used in) investing activities | (63,583) | (54,769) |
| Financing Activities |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s capex?
- Krystal Biotech, Inc. (KRYS) reported capex of $7.15M in Q1 2026.
- How has Krystal Biotech, Inc.'s capex changed year-over-year?
- Krystal Biotech, Inc.'s capex increased by 15.2% year-over-year, from $6.2M to $7.15M.
- What is the long-term trend for Krystal Biotech, Inc.'s capex?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s capex has grown at a -35.3% compound annual growth rate (CAGR), from $68.34M to $11.95M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Krystal Biotech, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude